FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Os...(ith teriparatide and 3.9 plus...),Health

3.9 plus or minus 0.6 percent increase with alendronate at 18

months (P < 0.001)

-- The mean increase in total hip BMD with teriparatide was significantly

greater compared with alendronate after 12 months (first measurement

at the hip) through 18 months of therapy

-- 3.8 plus or minus 0.6 percent increase with teriparatide and

2.4 plus or minus 0.6 percent increase with alendronate at 18

months (P < 0.01)

-- A preliminary analysis of new radiographic vertebral fractures in

patients with baseline and 18 month radiographs showed that one

patient receiving teriparatide (0.6 percent; 1 out of 171 patients)

and 10 patients receiving alendronate (6.1 percent; 10 out of 165

patients) had greater than or equal to 1 new vertebral fracture

-- A preliminary analysis of nonvertebral fracture showed that 12

patients receiving teriparatide (5.6 percent; 12 out of 214 patients)

and eight patients receiving alendronate (3.7 percent; 8 out of 214

patients) had greater than or equal to 1 new nonvertebral fracture

There was no significant difference overall in the number of patients reporting adverse events in patients receiving teriparatide compared with alendronate.(1) Significant differences between groups in individual adverse events included nausea, insomnia, pharyngitis, and viral infection reported by more patients receiving teriparatide than alendronate, and rash, weight decrease, sciatica, and asthma reported by more patients receiving alendronate than teriparatide.(1) A significantly higher proportion of teriparatide than alendronate patients had at least one post-baseline calcium in the hypercalcemia range (18.0 percent [38 out of 211 patients] for teriparatide and 5.7 percent [12 out of 207 patients] for alendronate (P < 0.001).(1)

To view the published manuscript,
'/>"/>